Mineralys Therapeutics Inc (MLYS)

$MLYS ok lets roll on back to 13 so I can get my shares back.

HC Wainwright & Co. has updated their rating for Mineralys Therapeutics ( $MLYS ) to Buy with a price target of 42.

$MLYS https://finance.yahoo.com/news/mineralys-therapeutics-inc-mlys-q2-071258707.html

$MLYS left the call wondering if “opine”was the company slogan 🤔

$MLYS - Mineralys Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors MLYS flags ongoing inflation into 2025 and highlights new risks from domestic and international elections, warning these could drive economic uncertainty and higher financing costs. #Biotechnology #PoliticalRisk #FinancingCosts #EconomicUncertainty #InflationRisk 🟢 Added 🟠 Removed https://d-risk.ai/MLYS/10-Q/2025-08-12

$MLYS "Heads up alert! Upcoming earnings on Tuesday, 8/12/2025 for $MLYS Bullish (8.4) --- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, has demonstrated promising advancements in its developmental pipeline, particularly with its lead candidate, lorundrostat. The recent publication in the Journal of the American Medical Association (JAMA) highlights the successful outcomes of its pivotal Phase 3 Launch-HTN trial, showing significant reductions in systolic blood pressure for patients with uncontrolled or treatment-resistant hypertension. This positions lorundrostat as a potential game-changer in the hypertension treatment landscape, with meaningful clinical efficacy and a favorable safety profile. The company's strategic focus on hypertension and related comorbidities is further underscored by the positive topline data from the Phase 2 Explore-CKD trial, which adds depth to its clinical portfolio. Financially, the company has caught the attention of analysts, with a recent upgrade to a Zacks Rank #2 (Buy) reflecting growing optimism about its earnings prospects. Analysts have set a mean price target suggesting a potential upside of over 150%, indicating strong market confidence in Mineralys' future growth trajectory. Although the company is currently in a cash burn phase typical of clinical-stage biopharmaceuticals, the positive trial outcomes are likely to bolster investor confidence. Comparatively, Mineralys is positioned favorably among its small-cap peers, particularly due to its focused approach and promising pipeline. --- Mineralys Therapeutics is set to announce its second-quarter 2025 financial results on August 12, 2025. This announcement is highly anticipated, as it will provide insights into the company's financial health, cash position, and potential impacts of recent clinical developments on its financial trajectory. Historically, the company has been in a developmental phase, with a focus on advancing its clinical trials. Analyst consensus estimates are likely to focus on the company's cash runway and any updates on partnerships or funding that could influence its financial stability. The upcoming earnings report will be pivotal in assessing the company's progress and strategic direction. --- The broader biotechnology sector, to which Mineralys belongs, has shown resilience and growth, driven by innovation and a robust pipeline of new treatments. Despite market volatility, the sector continues to attract investor interest due to its potential for high returns, particularly for companies with breakthrough therapies. Mineralys' focus on hypertension and its innovative approach with lorundrostat align well with sector trends, which prioritize unmet medical needs and novel therapeutic solutions. - Funds were net buyers of $MLYS during the previous reporting quarter. - Funds with large holdings in $MLYS include: - RA Capital Management LLC, MV: $98MM. Fund Rank: 58% www.racap.com - Samsara BioCapital LLC, MV: $90MM. Fund Rank: 57% www.samsaracap.com - Suvretta Capital Management LLC, MV: $26MM. New position. Fund Rank: 79% www.suvcap.com - Nantahala Capital Management LLC, MV: $13MM. Fund Rank: 67% www.nantahalapartners.com - DAFNA Capital Management LLC, MV: $5MM. Fund Rank: 58% www.dafnacapital.com - Last 10 days performance: -6% - Last 30 days performance: -8% - Last 90 days performance: -9% Some of the latest news articles: - Title: Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 Publication Date: 8/4/2025 8:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/mineralys-therapeutics-announce-second-quarter-200500403.html?.tsrc=rss - Title: Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why Publication Date: 7/25/2025 4:00:02 PM, Source: yahoo URL: https://finance.yahoo.com/news/mineralys-therapeutics-inc-mlys-upgraded-160002884.html?.tsrc=rss - Title: Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? Publication Date: 7/25/2025 1:55:01 PM, Source: yahoo URL: https://finance.yahoo.com/news/does-mineralys-therapeutics-inc-mlys-135501224.html?.tsrc=rss - Title: Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation Publication Date: 7/2/2025 1:01:07 PM, Source: yahoo URL: https://finance.yahoo.com/news/heres-why-were-watching-mineralys-130107797.html?.tsrc=rss Follow us on stocktwits.com. Not a financial advice. Not a trading signal."

$MLYS kind of bouncing the trading range of 12.90 to 15.10 or so. This company needs a marketing and production partner in a big way to get over the Jeffries analyst target snag of 15 since competition with big marketing power has a similar drug getting ready.

$MLYS Outstanding article that hits the mark on MLYS's current state. So if you want to refresh your MLYS insights or learn about MLYS from scratch, this is a must read. https://beyondspx.com/article/mineralys-therapeutics-unlocking-value-in-hypertension-with-lorundrostat-s-differentiated-profile-mlys

for all the haters out there, occasionally I take a loss. sold 75 $RARE today 7/23 at a loss but got a whopping 28.14. Paid 29.51 and 29.23 for it. it ended at 28.01 so I feel pretty good about it. I still own 101 but felt like I HAD 2 UNLOAD some on a super up day. also, lost real money on $MLYS 7 15 b 130 at 14.57 7 23 today 7 130 at 13.36 did everybody see that $EUFN Europe Financials was up tons 4.17% ditto France $EWQ up 3.1% trimmed $SCJ today 7/23 at a price higher than the close s 185 at 86.5535 It closed at 86.46

$XBI b100 86.27 on a mkt on close order b additional 50 $EWJ mkt on close today 7/18/25 71.81 7/7 I / we / grandpa / + 2 cousins bot a boatload of $EWJ together 72.69 unable to re-enter $MLYS 14.18 closed at 14.23 new topic: trump sues NEWS CORP $NWS for libel